Published in
American Association for the Advancement of Science, Science Translational Medicine, 580(13), 2021
DOI: 10.1126/scitranslmed.abc4465
Links
Tools
Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types
Journal article published in 2021 by
Qi Liu 
,
Luis Palomero ,
Jade Moore ,
Ines Guix,
Roderic Espín ,
Alvaro Aytés,
Jian-Hua Mao ,
Amanda G. Paulovich ,
Jeffrey R. Whiteaker ,
Richard G. Ivey ,
George Iliakis ,
Daxian Luo,
Anthony J. Chalmers ,
John Murnane,
Miquel Angel Pujana
and other authors.
,
Luis Palomero ,
Jade Moore ,
Ines Guix,
Roderic Espín ,
Alvaro Aytés,
Jian-Hua Mao ,
Amanda G. Paulovich ,
Jeffrey R. Whiteaker ,
Richard G. Ivey ,
George Iliakis ,
Daxian Luo,
Anthony J. Chalmers ,
John Murnane,
Miquel Angel Pujana
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
The impact of TGFβ signaling on DNA repair competency is observed in a pan-cancer analysis of survival after treatments that cause DNA damage.